8-K: AngioDynamics Presents at J.P. Morgan Healthcare Conference, Outlines Growth Strategy

AngioDynamics presented at the J.P. Morgan 43rd Annual Healthcare Conference, highlighting its strategic focus on high-growth Med Tech segments and its path to profitability.

Summary

• AngioDynamics presented at the J.P. Morgan 43rd Annual Healthcare Conference on January 16, 2025.
• The company is focused on cardiovascular disease and cancer treatment, with a strategy built on innovative R&D, clinical and regulatory expansion, and customer-centric sales.
• AngioDynamics operates through two segments: Med Tech and Med Device.
• The Med Tech segment is experiencing high growth and now contributes over 40% of total revenue.
• The company expects to be adjusted EBITDA positive by fiscal year 2025 and cash flow positive by fiscal year 2026.
• Fiscal year 2024 pro forma revenue was $271 million.
• The company has divested several businesses including Dialysis & BioSentry, Port Patent, and PICC & Midlines to focus on core growth areas.
• The Med Tech segment includes platform technologies such as NanoKnife for prostate cancer, AngioVac and AlphaVac for venous thromboembolism, and Auryon for peripheral artery disease.
• The company is targeting large addressable markets, including a $5.3 billion US market for venous thromboembolism, a $780 million US market for prostate care, and a $760 million US market for peripheral artery disease.
• The company is restructuring its manufacturing footprint, which is estimated to save $15 million in fiscal year 2027.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with a clear path to profitability and growth, but also acknowledges risks and challenges. The company is making progress in key areas, but still has work to do to achieve its goals.

Positives

• The Med Tech segment is experiencing strong growth and is becoming a larger part of the company's revenue.
• The company has a clear path to profitability with expected adjusted EBITDA positivity in fiscal year 2025 and cash flow positivity in fiscal year 2026.
• AngioDynamics has a strong balance sheet with no debt.
• The company has a diversified portfolio of innovative technologies targeting large and growing markets.
• The company has a track record of successful portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing.
• The company is actively divesting non-core assets to focus on high-growth areas.
• The company is expanding into new indications and markets with its existing technologies.
• The company has a leverageable infrastructure to support future growth.

Negatives

• The Med Device segment is experiencing flat to negative growth.
• The company is currently not profitable, with an adjusted EPS loss of ($0.15) year-to-date in 2025.
• The company is still reliant on the Med Device segment to fund the Med Tech segment.
• The company faces competition from larger companies with greater resources.
• The company is subject to risks and uncertainties, including the impact of the COVID-19 pandemic, regulatory approvals, and economic conditions.

Risks

• The company's future performance is subject to risks and uncertainties, including the scale and scope of the COVID-19 pandemic.
• The company's ability to develop new products and compete with larger companies is a risk.
• Regulatory approvals and changes in healthcare reforms could impact the company's business.
• Economic conditions, including inflation, labor shortages, and supply chain challenges, could affect the company's results.
• Ongoing litigation and product liability claims could negatively impact the company.
• The company's ability to execute on strategic initiatives and integrate acquired businesses is a risk.
• The company is subject to market acceptance and foreign currency exchange rate fluctuations.

Future Outlook

AngioDynamics expects to be adjusted EBITDA positive by fiscal year 2025 and cash flow positive by fiscal year 2026, with sustainable revenue growth and profit for years to come.

Management Comments

• Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics business over time.
• Management believes that these measures provide investors with useful information in comparing AngioDynamics performance over different periods.
• Management encourages investors to review AngioDynamics financial results prepared in accordance with GAAP to understand AngioDynamics performance taking into account all relevant factors.

Industry Context

AngioDynamics operates in the medical technology industry, focusing on cardiovascular disease and cancer treatment, which are large and growing markets. The company's focus on innovative technologies and strategic portfolio management aligns with industry trends towards minimally invasive procedures and improved patient outcomes. The company is competing with larger players in the space, but is focusing on niche markets and differentiated technologies.

Comparison to Industry Standards

• The document references a Truist equity research note from January 25, 2024, which suggests that AngioDynamics is being compared to other Med Tech Cardiovascular companies.
• The document mentions Penumbra, Inc. as a comparable company in the context of mechanical thrombectomy.
• The document highlights the market penetration of mechanical thrombectomy for Deep Vein Thrombosis (DVT) at approximately 15%, and Pulmonary Embolism (PE) at approximately 25%, which are key metrics for comparison with other companies in the space.
• The document also provides market growth estimates for mechanical thrombectomy, with 20% growth expected in 2025 for DVT and 16% for PE, which can be compared to industry growth rates.
• The document compares the clot reduction results of the AlphaVac system in the APEX study to the FLARE and EXTRACT-PE studies, which used the FlowTriever and Indigo systems respectively, providing a direct comparison to competitor technologies.

Stakeholder Impact

• Shareholders can expect potential growth and profitability in the future.
• Employees may see opportunities for growth and development within the company.
• Customers will benefit from innovative technologies and improved patient outcomes.
• Suppliers may see increased demand for their products and services.
• Creditors may see improved financial stability and creditworthiness of the company.

Next Steps

• The company will continue to focus on R&D, clinical and regulatory expansion, and customer-centric sales.
• The company will continue to execute on its strategic initiatives.
• The company will begin enrollment in the AMBITION BTK study in Q1 2025.

Key Dates

Keywords

Med Tech, Medical Devices, Cardiovascular Disease, Cancer, Thrombectomy, Prostate Cancer, Peripheral Artery Disease, NanoKnife, AngioVac, AlphaVac, Auryon, EBITDA, Revenue, Healthcare